Skip to content
drillr.ai
Sign up

02696.HK

Shanghai Henlius Biotech, Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 49.06
−1.72%
Ask drillr

  • Oct 22, 2026, 10:38 UTC

    GIC Private Limited increased its holding in Shanghai Henlius Biotech, Inc. by 592,000 H shares at an average HK$52.5738 per share, raising its stake to 6.08%.

    Source:

  • Oct 19, 2026, 13:23 UTC

    Shanghai Henlius Biotech, Inc. reported positive results from its ASTRIDE study of serplulimab as first-line treatment for extensive-stage small-cell lung cancer, with 201 patients enrolled at 63 U.S. research centers and median overall survival of 12.4 months.

    Source:

  • Sep 23, 2026, 08:37 UTC

    Shanghai Henlius Biotech, a controlling subsidiary of Fosun Pharma, signed a cooperation and license agreement with Amberstone on September 23, 2026, obtaining an exclusive global license to research, develop, manufacture and commercialize two products based on the T-MATE™ technology platform for agreed targets.

    Source:

  • Sep 21, 2026, 02:12 UTC

    Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.

    Source:

  • Sep 18, 2026, 05:45 UTC

    Sandoz announced a licensing, development, manufacturing and commercialisation agreement with mAbxience for a proposed emicizumab biosimilar, with Sandoz holding exclusive global commercialisation rights excluding Argentina, Uruguay and Paraguay.

    Source:

  • Sep 11, 2026, 08:34 UTC

    Shanghai Henlius Biotech's marketing registration application (NDA) for its self-developed denosumab biosimilar HLX14 (120mg/1.7ml vial) was accepted by the NMPA Center for Drug Evaluation.

    Source:

  • Sep 7, 2026, 04:35 UTC

    Shanghai Henlius Biotech was added to the Stock Connect southbound trading list effective September 7, allowing eligible mainland Chinese investors to trade its shares via Shanghai and Shenzhen exchanges.

    Source:

  • Aug 26, 2026, 13:54 UTC

    Alligator Bioscience announced it is abandoning independent development of its lead cancer drug mitazalimab, shifting to a leaner model focused on its royalty interest in HLX22, and reducing staff and operating costs.

    Source:

  • Aug 26, 2026, 10:52 UTC

    GIC Private Limited increased its stake in Shanghai Henlius Biotech (02696.HK) to 5.03% by buying 232,200 H-shares at an average price of HK$68.6666 per share on August 21, 2026.

    Source:

  • Aug 21, 2026, 12:16 UTC

    Shanghai Henlius Biotech disclosed its interim results for the first half of 2026, reporting revenue of 3.5882 billion yuan, up 27.3% year-on-year, and net profit of 430.4 million yuan, up 10.3%.

    Source:

  • Aug 21, 2026, 12:16 UTC

    Shanghai Henlius Biotech was selected for inclusion in the Hang Seng Composite Index, effective September 7, 2026, following the latest quarterly review by Hang Seng Indexes Company.

    Source:

  • Aug 16, 2026, 23:48 UTC

    Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.

    Source:

  • Jul 31, 2026, 08:34 UTC

    Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.

    Source:

  • Jul 30, 2026, 09:27 UTC

    Shanghai Henlius Biotech (02696) announced that the first patient has been dosed in a Phase 1 clinical study of its self-developed HLX3902 injection for metastatic castration-resistant prostate cancer and other advanced solid tumors in China (excluding Hong Kong, Macau, and Taiwan).

    Source:

  • Jul 16, 2026, 08:37 UTC

    Shanghai Henlius Biotech (02696) announced that its self-developed nivolumab biosimilar HLX18 has completed first patient dosing in a Phase 1 clinical trial in China for multiple resected solid tumors.

    Source:

  • Jul 10, 2026, 08:35 UTC

    Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.

    Source:

  • Jun 25, 2026, 20:57 UTC

    Shanghai Henlius Biotech announced that the European Commission approved serplulimab for first-line treatment of squamous non-small cell lung cancer, its fourth EU indication.

    Source:

  • Jun 23, 2026, 09:30 UTC

    Organon Canada and Shanghai Henlius Biotech launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA, in Canada.

    Source: